# Patent cliffs and the generics counterattack
In January 2023, 132 lawyers, patent examiners, and biosimilar developers were watching a single date on the calendar: the day AbbVie's Humira, the best-selling drug in pharmaceutical history, finally lost its US patent protection. It had earned over $200 billion in cumulative sales (estimate, AbbVie financial disclosures). Yet a year later, AbbVie was still capturing the majority of that market. That gap between "patent expired" and "revenue collapsed" is the entire subject of this lesson.
A patent cliff is the steep revenue drop a drug faces when its patent protection ends and competitors launch cheaper copies. In the US, this triggers generic competition for small-molecule drugs (chemically synthesized, like ibuprofen) and biosimilar competition for biologics (complex molecules made from living cells, like Humira).
The distinction matters for power dynamics. Generics must prove bioequivalence, chemical sameness, which is relatively cheap to demonstrate. Biosimilars must prove "no clinically meaningful difference" from the original, which requires costly clinical trials. This is why biosimilars have historically eroded originator revenue more slowly than generics do.
Loss of exclusivity (LOE) is the industry term for this whole event: the moment a drug's protected monopoly period ends.
Originators (AbbVie, Pfizer, Merck) built the drug and want to extend the profitable monopoly as long as possible.
Challengers (generic and biosimilar makers like Teva, Sandoz, Amgen, Viatris) want to enter fast and grab share before prices fully collapse.
Payers and Pharmacy Benefit Managers (PBMs) like CVS Caremark, Express Scripts, and OptumRx sit between manufacturers and patients in the US, negotiating rebates and deciding which drugs get preferred placement on formularies (the list of covered drugs).
Regulators: the FDA (US Food and Drug Administration) approves generics and biosimilars; the EMA (European Medicines Agency) does the equivalent in the EU. Antitrust bodies like the FTC (Federal Trade Commission) and the European Commission police anti-competitive patent behavior.
AbbVie didn't rely on one patent for Humira. It built a patent thicket: a dense web of over 100 patents covering the drug's formulation, manufacturing process, dosing regimens, and delivery device, filed at different times to push expiration dates further out.
The core Humira patent expired in 2016. Actual biosimilar competition didn't arrive in the US until 2023, seven years later. In Europe, where patent thickets are harder to sustain and the EMA approved Humira biosimilars back in 2018, competition arrived far sooner and prices fell faster (estimate: some European markets saw price drops of 80%+ within two years, per European Commission biosimilars reporting).
This gap illustrates a core power dynamic: originators use IP law and regulatory complexity as competitive weapons, and the effectiveness of that weapon differs by jurisdiction.
Other originator defense tactics:
This is the counterintuitive part students often miss: even after nine biosimilars launched in the US in 2023, AbbVie retained an estimated majority of Humira's US market sharemarket shareThe percentage of total industry sales your company captures in a given period. It measures competitive position relative to rivals in a defined market.View full definition → through 2024 (estimate, based on AbbVie earnings commentary).
Why? Because in the US, formulary placement decided by PBMs matters more than list price. Biosimilar makers had to negotiate their way onto formularies, competing on rebates to PBMs rather than just on price to patients. AbbVie's existing rebate relationships gave it a defensive moatmoatA lasting edge over competitors: a resource, capability or position they cannot easily replicate, letting a firm earn above-average returns over time.View full definition → that had nothing to do with patents.
This is a critical lesson in pharma power dynamics: patent law determines when competition is legally allowed to start; distribution and payer relationships determine how much that competition actually bites.
Biosimilar and generic makers compete on:
Companies like Sandoz (spun off from Novartis in 2023 specifically to focus on generics and biosimilars) and Viatris (formed from the Mylan-Pfizer Upjohn merger) exist because this is a distinct enough business, low margin, high volume, regulatory-arbitrage-driven, that it benefits from separation from high-margin innovator pharma.
Knowledge check
1. Why do biosimilars typically erode an originator biologic's revenue more slowly than generics erode a small-molecule drug's revenue?
2. A drug's patent expires, but a year later the originator still holds the majority of the market. What does this gap between 'patent expired' and 'revenue collapsed' primarily illustrate?
3. A PBM decides to give a newly launched biosimilar preferred placement on its formulary while the originator drug is moved to a less favorable tier. What is the most likely effect of this decision?
4. Select ALL correct answers describing key differences between generics and biosimilars.
Select all the correct answers.
5. Select ALL correct answers about the incentives of different players during a patent cliff.
Select all the correct answers.
Who actually captures the margin as a drug moves through its lifecycle?
Pre-LOE (on-patent): originator captures the overwhelming majority of value. List prices are high; PBM rebates carve out a meaningful slice (often 30-50% of list price in the US, estimate) but the manufacturer still nets high margins.
Post-LOE, generics (small molecule): price collapses fast, often 80-90% within 1-2 years in the US. Margin shifts to whichever generic manufacturer achieves lowest-cost production at scale. Distributors (McKesson, Cencora, Cardinal Health) take a smaller but stable cut regardless of which manufacturer wins.
Post-LOE, biosimilars: price erosion is slower and shallower (often 30-50% over several years, estimate), because manufacturing complexity limits the number of viable entrants and payer/PBM dynamics slow substitution. Margin stays split longer between originator and a handful of biosimilar makers.
Worked illustration: Assume Humira's US net price pre-LOE was roughly $80,000/year per patient (estimate, based on list price minus typical rebates). If a biosimilar enters at a 30% discount, that's roughly $56,000. If PBM formulary dynamics keep the originator's effective net price competitive through rebates, the originator can defend share even without matching the sticker discount, because payers care about net cost after rebate, not list price. This is why headline "biosimilar discount" percentages often overstate the actual competitive threat in year one.
Europe generally sees faster, deeper biosimilar erosion because:
This is a useful comparison for understanding how the same molecule can face completely different power dynamics depending on payer structure.
🎬 [VIDEO: "How Drug Patents Work (And How Companies Extend Them)" - youtube.com - search for recent explainers from Marginal Revolution University or similar economics education channels covering pharma IP strategy]
For a regulatory primer, the FDA's biosimilars overview is a solid, free, authoritative reference.